+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class and Therapy Type: Global Opportunity Analysis and Industry Forecast, 2021-2030

  • PDF Icon

    Report

  • 216 Pages
  • January 2022
  • Region: Global
  • Allied Market Research
  • ID: 5561134
The global benign prostatic hyperplasia therapeutics market was valued at $5,697.70 million in 2020, and is estimated to reach $9,391.50 million by 2030, growing at a CAGR of 5.00% from 2021 to 2030.



The prostate is a walnut-sized gland that surrounds the urethra in the male reproductive system. The main function of this gland is to secrete a fluid, which mixes with the fluids from other glands and sperm cells from the testicles to generate semen. Benign prostatic hyperplasia (BPH) is a non-malignant increase in the size of the prostate gland. It is also called benign prostatic hypertrophy or benign prostatic obstruction. As a man gets older, his prostate goes through two major growth stages. The first happens when the prostate doubles in size throughout adolescence. The second stage of development begins at the age of 25 and lasts for the rest of a man's life. The BPH is common during the second growth phase.

As the prostate gland grows larger, it presses against and pinches the urethra. The bladder's lining thickens. It prevents urine from flowing freely from the bladder, resulting in nighttime urination, urinary hesitation, trouble starting to urinate, a weak urine stream or a stream that stops and begins, dribbling at the end of urination, and a sense of urgency to urinate. The bladder's ability to empty completely may weaken over time, causing urinary retention by leaving some urine in the bladder. Many of the symptoms of benign prostatic hyperplasia are caused by urethral constriction and urine retention, or the inability to empty the bladder entirely. Because of symptoms like urine leakage and nocturia, BPH has a substantial impact on the patient's quality of life. If untreated for a long duration, it results in more serious health issues, such as bladder damage, bladder stones, kidney damage, and urinary tract infections (UTIs). Moreover, lower urinary tract symptoms (LUTS) are becoming more common in both men and women as they get older. LUTS is frequently associated with benign prostatic hyperplasia in men (BPH)

This market is majorly driven by an increase in the male geriatric population because the disease generally occurs in men of age 50 and above. For instance, according to The administration for Community Living, which includes the administration on Aging, is an operating division of the U.S. Department of Health and Human Services. In 2019, the American population aged above 65 was 54.1 million among which about 24.1million were men. The overall population aged 65 and older increased from 39.6 million in 2009 to 54.1 million in 2019 a 36% increase and is projected to reach 94.7 million in 2060. By 2040, there will be about 80.8 million older persons, more than twice as many as in 2000. Thus, such increase in older population especially in males is anticipated to drive the growth of the market. In addition, according to The Official Foundation of the American Urological Association about half of all men aged between 51 and 60 years and up to 90% of men over age 80 have BPH.

The other factors boosting the market growth include increase in unhealthy lifestyle among the population, growth in awareness related to urological disorders, early diagnosis of the medical condition, rise in prostate cancer cases and rise in the number of global benign prostatic hyperplasia patients. In addition, a family history of erectile dysfunction, obesity, type 2 diabetes, insufficient exercise, and erectile dysfunction are all risk factors of BPH. The alpha blocker, 5-alpha reductase inhibitor, phosphodiesterase-5 inhibitor therapeutic class of drugs are the majorly used. Furthermore, antimuscarinics, anticholinergic agents, and beta 3 adrenoreceptor are also used.

However, preferences for minimally-invasive surgeries namely, laparoscopic prostatectomy, transurethral needle ablation (TUNA), and transurethral microwave thermotherapy (TUMT), hinder the growth of the global BPH therapeutics market. Furthermore, presence of a plethora of products in the pipeline and high market potential in untapped emerging economies are anticipated to serve as attractive opportunities during the forecast period.

The global benign prostatic hyperplasia therapeutics market is segmented on the basis of therapeutic class, therapy, and region. On the basis of therapeutic class, the market is categorized into alpha blocker, 5-alpha reductase inhibitor, phosphodiesterase-5 inhibitor, and others. By therapy, the market is bifurcated into mono drug therapy and combination drug therapy. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America Middle East and Africa (LAMEA)

The major players profiled in the report are Abbott Laboratories, AbbVie (Allergan Plc), Astellas Pharma Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Eli Lilly and Company, GlaxoSmithKline plc., Merck & Co., Inc. (Merck Sharp & Dohme Corp), Pfizer Inc., Sanofi and Teva Pharmaceutical Industries Limited.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global benign prostatic hyperplasia therapeutics market to identify the prevailing opportunities.
  • This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
  • Comprehensive analysis of factors that drive and restrict the market growth is provided.
  • Region-& country-wise analysis is provided to understand the market trends and dynamics

KEY MARKET SEGMENTS


By Therapeutics Class

  • Alpha blockers
  • 5-alpha reductase inhibitors
  • Phosphodiesterase-5 inhibitors
  • Other

By Therapy

  • Mono drug therapy
  • Combination drug therapy

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • South Africa
  • Saudi Arabia
  • Rest of LAMEA

KEY MARKET PLAYERS

  • Abbott Laboratories
  • AbbVie (Allergan Plc)
  • Astellas Pharma Inc.
  • Boehringer Ingelheim Pharma GmbH & Co. KG
  • Eli Lilly and Company
  • GlaxoSmithKline plc.
  • Merck & Co., Inc. (Merck Sharp & Dohme Corp)
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Limited
Frequently Asked Questions about the Global Benign Prostatic Hyperplasia Therapeutics Market

What is the estimated value of the Global Benign Prostatic Hyperplasia Therapeutics Market?

The Global Benign Prostatic Hyperplasia Therapeutics Market was estimated to be valued at $5697.7 million in 2020.

What is the growth rate of the Global Benign Prostatic Hyperplasia Therapeutics Market?

The growth rate of the Global Benign Prostatic Hyperplasia Therapeutics Market is 5.1%, with an estimated value of $9391.5 million by 2030.

What is the forecasted size of the Global Benign Prostatic Hyperplasia Therapeutics Market?

The Global Benign Prostatic Hyperplasia Therapeutics Market is estimated to be worth $9391.5 million by 2030.

Who are the key companies in the Global Benign Prostatic Hyperplasia Therapeutics Market?

Key companies in the Global Benign Prostatic Hyperplasia Therapeutics Market include Abbott Laboratories, AbbVie (Allergan Plc), Astellas Pharma Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Eli Lilly and Company, GlaxoSmithKline plc., Merck & Co., Inc., (Merck Sharp & Dohme Corp) and Sanofi.

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profile in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in geriatric population
3.5.1.2. Surge in prevalence of benign prostatic hyperplasia
3.5.1.3. Increase in awareness toward urological disorders
3.5.1.4. Surge in healthcare expenditure worldwide
3.5.2. Restraint
3.5.2.1. High preference for minimally invasive surgical therapies
3.5.3. Opportunities
3.5.3.1. Large number of products in pipeline
3.5.3.2. Lucrative opportunities in emerging markets
3.6. Impact analysis
3.7. Impact analysis of COVID-19 on the benign prostatic hyperplasia therapeutics market
3.8. Clinical trials analysis, 2019-2022
CHAPTER 4: BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Alpha blockers
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3.5- alpha reductase inhibitors
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Phosphodiesterase-5 inhibitors
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Others
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
CHAPTER 5: BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY
5.1. Overview
5.1.1. Market size and forecast
5.2. Mono drug therapy
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Combination drug therapy
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
CHAPTER 6: BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America benign prostatic hyperplasia therapeutics market, by therapeutic class
6.2.3. North America benign prostatic hyperplasia therapeutics market, by therapy
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. U.S. benign prostatic hyperplasia therapeutics market, by therapeutic class
6.2.4.1.2. U.S. benign prostatic hyperplasia therapeutics market, by therapy
6.2.4.2. Canada
6.2.4.2.1. Canada benign prostatic hyperplasia therapeutics market, by therapeutic class
6.2.4.2.2. Canada benign prostatic hyperplasia therapeutics market, by therapy
6.2.4.3. Mexico
6.2.4.3.1. Mexico benign prostatic hyperplasia therapeutics market, by therapeutic class
6.2.4.3.2. Mexico benign prostatic hyperplasia therapeutics market, by therapy
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe benign prostatic hyperplasia therapeutics market, by therapeutic class
6.3.3. Europe benign prostatic hyperplasia therapeutics market, by therapy
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Germany benign prostatic hyperplasia therapeutics market, by therapeutic class
6.3.4.1.2. Germany benign prostatic hyperplasia therapeutics market, by therapy
6.3.4.2. France
6.3.4.2.1. France benign prostatic hyperplasia therapeutics market, by therapeutic class
6.3.4.2.2. France benign prostatic hyperplasia therapeutics market, by therapy
6.3.4.3. UK
6.3.4.3.1. UK benign prostatic hyperplasia therapeutics market, by therapeutic class
6.3.4.3.2. UK benign prostatic hyperplasia therapeutics market, by therapy
6.3.4.4. Italy
6.3.4.4.1. Italy benign prostatic hyperplasia therapeutics market, by therapeutic class
6.3.4.4.2. Italy benign prostatic hyperplasia therapeutics market, by therapy
6.3.4.5. Spain
6.3.4.5.1. Spain benign prostatic hyperplasia therapeutics market, by therapeutic class
6.3.4.5.2. Spain benign prostatic hyperplasia therapeutics market, by therapy
6.3.4.6. Rest of Europe
6.3.4.6.1. Rest of Europe benign prostatic hyperplasia therapeutics market, by therapeutic class
6.3.4.6.2. Rest of Europe benign prostatic hyperplasia therapeutics market, by therapy
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific benign prostatic hyperplasia therapeutics market, by therapeutic class
6.4.3. Asia-Pacific benign prostatic hyperplasia therapeutics market, by therapy
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Japan benign prostatic hyperplasia therapeutics market, by therapeutic class
6.4.4.1.2. Japan benign prostatic hyperplasia therapeutics market, by therapy
6.4.4.2. China
6.4.4.2.1. China benign prostatic hyperplasia therapeutics market, by therapeutic class
6.4.4.2.2. China benign prostatic hyperplasia therapeutics market, by therapy
6.4.4.3. Australia
6.4.4.3.1. Australia benign prostatic hyperplasia therapeutics market, by therapeutic class
6.4.4.3.2. Australia benign prostatic hyperplasia therapeutics market, by therapy
6.4.4.4. India
6.4.4.4.1. India benign prostatic hyperplasia therapeutics market, by therapeutic class
6.4.4.4.2. India benign prostatic hyperplasia therapeutics market, by therapy
6.4.4.5. South Korea
6.4.4.5.1. South Korea benign prostatic hyperplasia therapeutics market, by therapeutic class
6.4.4.5.2. South Korea benign prostatic hyperplasia therapeutics market, by therapy
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Rest of Asia-Pacific benign prostatic hyperplasia therapeutics market, by therapeutic class
6.4.4.6.2. Rest of Asia-Pacific benign prostatic hyperplasia therapeutics market, by therapy
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. LAMEA benign prostatic hyperplasia therapeutics market, by therapeutic class
6.5.3. LAMEA benign prostatic hyperplasia therapeutics market, by therapy
6.5.4. LAMEA benign prostatic hyperplasia therapeutics market, by country
6.5.4.1. Brazil
6.5.4.1.1. Brazil benign prostatic hyperplasia therapeutics market, by therapeutic class
6.5.4.1.2. Brazil benign prostatic hyperplasia therapeutics market, by therapy
6.5.4.2. Saudi Arabia
6.5.4.2.1. Saudi Arabia benign prostatic hyperplasia therapeutics market, by therapeutic class
6.5.4.2.2. Saudi Arabia benign prostatic hyperplasia therapeutics market, by therapy
6.5.4.3. South Africa
6.5.4.3.1. South Africa benign prostatic hyperplasia therapeutics market, by therapeutic class
6.5.4.3.2. South Africa benign prostatic hyperplasia therapeutics market, by therapy
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Rest of LAMEA benign prostatic hyperplasia therapeutics market, by therapeutic class
6.5.4.4.2. Rest of LAMEA benign prostatic hyperplasia therapeutics market, by therapy
CHAPTER 7: COMPANY PROFILES
7.1. ABBOTT LABORATORIES
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.2. ABBVIE INC. (ALLERGAN INC.)
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.3. ASTELLAS PHARMA INC.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. ELI LILLY AND COMPANY
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6. GLAXOSMITHKLINE PLC.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.7. MERCK & CO. INC. (MERCK SHARP & DOHME CORP.)
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. PFIZER INC.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.9. SANOFI
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments
List of Tables
TABLE 01. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY CLINICAL TRIALS
TABLE 02. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020–2030 ($MILLION)
TABLE 03. ALPHA BLOCKERS MARKET, BY REGION, 2021-2030 ($MILLION)
TABLE 04.5- ALPHA REDUCTASE INHIBITORS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 05. PHOSPHODIESTERASE-5 INHIBITORS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 06. OTHERS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 07. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020–2030 ($MILLION)
TABLE 08. MONO DRUG THERAPY, BY REGION, 2020–2030 ($MILLION)
TABLE 09. COMBINATION DRUG THERAPY, BY REGION, 2020–2030($MILLION)
TABLE 10. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 11. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 12. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 13. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 14. U.S. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 15. U.S. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 16. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 17. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 18. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 19. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 20. EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 21. EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 22. EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 23. GERMANY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 24. GERMANY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 25. FRANCE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 26. FRANCE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 27. UK BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 28. UK BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 29. ITALY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 30. ITALY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 31. SPAIN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 32. SPAIN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 33. REST OF EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 34. REST OF EUROPE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 35. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 36. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 37. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 38. JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 39. JAPAN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 40. CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 41. CHINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 42. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 43. AUSTRALIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 44. INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 45. INDIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 46. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 47. SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 48. REST OF ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 49. REST OF ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 50. LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 51. LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 52. LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 53. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 54. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 55. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 56. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 57. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 58. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 59. REST OF LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPEUTIC CLASS, 2020-2030 ($MILLION)
TABLE 60. REST OF LAMEA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, BY THERAPY, 2020-2030 ($MILLION)
TABLE 61. ABBOTT: COMPANY SNAPSHOT
TABLE 62. ABBOTT: OPERATING SEGMENTS
TABLE 63. ABBOTT: PRODUCT PORTFOLIO
TABLE 64. ABBVIE: COMPANY SNAPSHOT
TABLE 65. ABBVIE: PRODUCT SEGMENT
TABLE 66. ABBVIE: PRODUCT PORTFOLIO
TABLE 67. ASTELLAS: COMPANY SNAPSHOT
TABLE 68. ASTELLAS: OPERATING SEGMENTS
TABLE 69. ASTELLAS: PRODUCT PORTFOLIO
TABLE 70. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 71. BOEHRINGER INGELHEIM: OPERATING SEGMENTS
TABLE 72. BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 73. LILLY: COMPANY SNAPSHOT
TABLE 74. LILLY: OPERATING SEGMENTS
TABLE 75. LILLY: PRODUCT PORTFOLIO
TABLE 76. GSK: COMPANY SNAPSHOT
TABLE 77. GSK: PRODUCT SEGMENTS
TABLE 78. GSK: PRODUCT PORTFOLIO
TABLE 79. MERCK: COMPANY SNAPSHOT
TABLE 80. MERCK: OPERATING SEGMENTS
TABLE 81. MERCK: PRODUCT PORTFOLIO
TABLE 82. PFIZER: COMPANY SNAPSHOT
TABLE 83. PFIZER: OPERATING BUSINESS SEGMENT
TABLE 84. PFIZER: PRODUCT PORTFOLIO
TABLE 85. SANOFI: COMPANY SNAPSHOT
TABLE 86. SANOFI: OPERATING SEGMENTS
TABLE 87. SANOFI: PRODUCT TYPE PORTFOLIO
TABLE 88. TEVA: COMPANY SNAPSHOT
TABLE 89. TEVA: OPERATING SEGMENTS
TABLE 90. TEVA: PRODUCT PORTFOLIO
TABLE 91. TEVA: KEY DEVELOPMENT
List of Figures
FIGURE 01. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 04. MODERATE BARGAINING POWER OF BUYERS
FIGURE 05. MODERATE THREAT OF SUBSTITUTES
FIGURE 06. HIGH THREAT OF NEW ENTRANTS
FIGURE 07. MODERATE INTENSITY OF RIVALRY
FIGURE 08. TOP PLAYER POSITIONING, 2020
FIGURE 09. IMPACT ANALYSIS
FIGURE 10. COMPARATIVE ANALYSIS OF ALPHA BLOCKERS MARKET, BY COUNTRY, 2021-2030 (%)
FIGURE 11. COMPARATIVE ANALYSIS OF 5- ALPHA REDUCTASE INHIBITORS MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 12. COMPARATIVE ANALYSIS OF PHOSPHODIESTERASE-5 INHIBITORS MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 13. COMPARATIVE ANALYSIS OF OTHERS MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 14. COMPARATIVE ANALYSIS OF MONO DRUG THERAPY, BY COUNTRY, 2020-2030 (%)
FIGURE 15. COMPARATIVE ANALYSIS OF COMBINATION DRUG THERAPY, BY COUNTRY, 2020-2030 (%)
FIGURE 16. ABBOTT: NET SALES, 2018–2020 ($MILLION)
FIGURE 17. ABBOTT: REVENU.S.ARE BY SEGMENT, 2020 (%)
FIGURE 18. ABBOTT: REVENU.S.ARE BY REGION, 2020(%)
FIGURE 19. ABBVIE: NET SALES, 2018–2020 ($MILLION)
FIGURE 20. ABBVIE: REVENU.S.ARE BY REGION, 2020(%)
FIGURE 21. ASTELLAS: NET SALES, 2018–2020 ($MILLION)
FIGURE 22. ASTELLAS: REVENU.S.ARE, BY SEGMENTS, 2020 (%)
FIGURE 23. ASTELLAS: REVENU.S.ARE, BY REGION, 2020 (%)
FIGURE 24. BOEHRINGER INGELHEIM: NET SALES, 2018–2020 ($MILLION)
FIGURE 25. BOEHRINGER INGELHEIM: REVENU.S.ARE, BY SEGMENTS, 2020 (%)
FIGURE 26. BOEHRINGER INGELHEIM: REVENU.S.ARE, BY REGION, 2020 (%)
FIGURE 27. LILLY: NET SALES, 2018–2020 ($MILLION)
FIGURE 28. LILLY: REVENU.S.ARE BY REGION, 2020(%)
FIGURE 29. GSK: NET SALES, 2018–2020 ($MILLION)
FIGURE 30. GSK: REVENU.S.ARE BY SEGMENT, 2020 (%)
FIGURE 31. GSK: REVENU.S.ARE BY REGION, 2020(%)
FIGURE 32. MERCK: NET SALES, 2018–2020 ($MILLION)
FIGURE 33. MERCK: REVENU.S.ARE, BY SEGMENTS, 2020 (%)
FIGURE 34. MERCK: REVENU.S.ARE, BY REGION, 2020 (%)
FIGURE 35. PFIZER: NET SALES, 2018–2020 ($MILLION)
FIGURE 36. PFIZER: REVENU.S.ARE BY REGION, 2020 (%)
FIGURE 37. SANOFI: REVENUE, 2018–2020 ($MILLION)
FIGURE 38. SANOFI: REVENU.S.ARE BY SEGMENT, 2020 (%)
FIGURE 39. SANOFI: REVENU.S.ARE BY REGION, 2020 (%)
FIGURE 40. TEVA: NET SALES, 2018–2020 ($MILLION)
FIGURE 41. TEVA: REVENU.S.ARE BY SEGMENT, 2020 (%)
FIGURE 42. TEVA: REVENU.S.ARE BY REGION, 2020(%)

Companies Mentioned

  • Abbott Laboratories
  • AbbVie (Allergan Plc)
  • Astellas Pharma Inc.
  • Boehringer Ingelheim Pharma GmbH & Co. KG
  • Eli Lilly and Company
  • GlaxoSmithKline plc.
  • Merck & Co., Inc.
  • (Merck Sharp & Dohme Corp)
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Limited

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...